Navigation Links
Neupro® (Rotigotine) Provided Clinically Relevant Improvements in Health-Related Quality of Life for People with Parkinson's Disease
Date:9/30/2010

all, 0.50 moderate, and 0.80 large effect). In the placebo group, the effect size (-0.06) and standardized response mean (-0.09) were low.

In a study of Asian patients, the PDQ-8 minimal important difference (MID) – defined as the smallest difference in score that informed patients/proxies would perceive as important and would lead the patient or clinician to consider a change in therapy – has been shown to range from 5.8-7.4 points.

"The change from baseline in PDQ-8 score in the rotigotine group was within the previously established MID range, suggesting that patients in the current study would consider the improvement in HRQL achieved by rotigotine to be important. The effect sizes indicate that the PDQ-8 is a responsive instrument and that rotigotine has a clinically relevant effect on HRQL," concluded Mr. Lilliu.

In the RECOVER study, the most frequently reported adverse events were nausea (rotigotine 21%, placebo 9%), application site reactions (rotigotine 15%, placebo 4%), and dizziness (rotigotine 10%, placebo 6%). In general, adverse drug reactions reported in more than 10% of Parkinson's patients treated with Neupro® are nausea, vomiting, application site reactions, somnolence, dizziness and headache.

Preclinical data showed rotigotine increased depth of sleep in ratsPreclinical data presented at the Congress showed that continuous administration of rotigotine or pulsatile L-DOPA had beneficial effects on wakefulness and sleep patterns in a rat model of Parkinson's disease, but only continuous rotigotine decreased the ratio of alpha to delta wave sleep during slow wave sleep, indicative of increased depth of sleep. To date the clinical significance of this finding has not been established.

The study was carried out to investigate the effects of rotigotine and pulsatile L-DOPA on sleep-wake patterns in a preclinical rat model of Parkinson's disease.

After two days of base
'/>"/>

SOURCE UCB
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. PNH Patients With Lower Levels of Hemolysis, Mild Anemia and Minimal Transfusion Support Have Significant Disease Burden; Soliris(R) Therapy Provided Clinical Improvements in PNH Patients Regardless of Disease Severity
2. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
5. Exenatide Once Weekly Provided Superior Glucose Control With Weight Loss Compared to Sitagliptin or Pioglitazone in Head-to-Head DURATION-2 Study
6. Exenatide Once Weekly Provided Sustained Improvements in Glycemic Control With Weight Loss Over Two Years: DURATION-1 Interim Long-Term Data Presented at ADA 2009
7. Exenatide Once Weekly Provided Superior Glucose Control Compared to Lantus(R) in Head-to-Head DURATION-3 Study
8. Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA(R) in DURATION-5 Study
9. Study Data Show INTUNIV™ (guanfacine) Extended Release Tablets Co-administered With Stimulants Provided ADHD Symptom Improvement in Children and Adolescents
10. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at 52 Weeks
11. New Data Demonstrates Victoza® (liraglutide [rDNA] injection) Provided Superior and Sustained Blood Sugar Control and Weight Reduction Compared to Januvia® (sitagliptin) at One Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014 Isis ... that it has earned a $4 million milestone ... ) associated with the initiation of a Phase ... multi-drug resistant (MDR), gram-negative bacterial infections.  The Phase ... to evaluate the efficacy and safety of plazomicin ...
(Date:9/17/2014)... Sutro Biopharma, a biopharmaceutical company developing antibody ... of Merck KGaA, Darmstadt, Germany , ... United States and Canada ... develop antibody drug conjugates (ADCs). ADCs are composed of ... is thought to specifically target and deliver the cytotoxic ...
(Date:9/17/2014)... , Sept. 17, 2014  Fortune Oil and Gas, ... its name to Manzo Pharmaceuticals, Inc. with the symbol ... effect today, September 17, 2014. Also taking effect today ... The approval is a pivotal event in the company,s ... Manzo explained, "We could not proceed with the plan ...
Breaking Medicine Technology:Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 2Fortune Oil and Gas, Inc. announces 1 for 10 reverse split along with a name change to Manzo Pharmaceuticals is now effective 3
(Date:9/17/2014)... for the very healthy. Astronauts are selected for ... psychological standards to prepare them for any unknown ... average people can now fly for enjoyment. The ... about what medical conditions or diseases should be ... most medical conditions have never been studied for ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Functional Fitness ... Ritchie and Dr. Cody Sipe that is helping middle-aged adults ... and longevity has caught the attention of Shane Michaels, prompting ... in their 50s, 60s, or even 70s what would be ... on a day-to-day basis, they would probably answer that the ...
(Date:9/17/2014)... -- Social networking sites can help people lose weight, ... are obese, sites like Twitter and Facebook can be ... as well as peers, researchers found. "One advantage ... it offers the potential to be much more cost ... traditional approaches," the study,s lead author, Dr. Hutan Ashrafian, ...
(Date:9/17/2014)... 2014 The Oliver Law Group P.C. ... caused by Non-Sterile Other-Sonic Ultrasound Transmission Gel to ... options for legal recourse. Other-Sonic ultrasound gel was recalled ... March 2012, after the product was linked to a ... Hospital in Royal Oak, Michigan . While victims of ...
(Date:9/17/2014)... (PRWEB) September 17, 2014 Catalent ... delivery technologies and development solutions for drugs, biologics ... of OptiPact™, an integrated service and technology offer ... and provided from the company’s 450,000 sq. ft. ... Catalent’s ability to integrate optimal formulation, development, analytical ...
Breaking Medicine News(10 mins):Health News:Space: The final frontier… open to the public 2Health News:Functional Fitness Solution: Review Exposes Dr. Dan Ritchie and Dr. Cody Sipe’s Guide to Everyday Fitness for Longevity 2Health News:Social Networking Sites Can Help Obese Lose Weight: Study 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 2Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 3Health News:Victims of Pseudomonas Infections Allegedly Caused by Other-Sonic Ultrasound Transmission Gel Face Statute of Limitations, Reports The Oliver Law Group P.C. 4Health News:New OptiPact™ Technology Introduced by Catalent 2
... ATLANTA, Aug. 11 MinuteClinic, the pioneer and largest provider ... a first-of-its kind rapid conjunctivitis (pink-eye) test at its 23 locations ... test is a pilot project conducted in partnership with Rapid Pathogen ... at a future date in its clinic locations in 25 states. ...
... PITTSBURGH, Aug. 11 Foundation Radiology ... headquartered in Pittsburgh, is pleased to announce its exclusive imaging ... , Uniontown Hospital, a 224-bed hospital, has ... of Fayette County and surrounding areas for over 100 years. ...
... , SOMERSET, N.J., Aug. 11 ... healthcare and administrative staffing services, will announce its third quarter financial results ... before the market opens. TeamStaff will host a conference call for ... Interested parties may participate in the call by dialing (877) ...
... , , , SAN ... CXM ) today reported its financial results for its second ... future outlook. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20051018/CARDIUMLOGO ... since first quarter 2009 financial report and highlights included (1) ...
... , , NEW YORK, Aug. ... a contract by ValueOptions(R), a behavioral health care company headquartered ... services for ValueOptions(R) at risk Plans, which cover approximately 1.5 ... Medicaid members that have other healthcare coverage, and recover overpayments ...
... MIAMI, Aug. 11 ECHealthInsurance.com a Florida based health ... month to help Floridians. According to Vice President of Marketing ... August is the only month every year that is open ... seasonality spikes of Florida our summer is much slower as ...
Cached Medicine News:Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 2Health News:MinuteClinic Offers New Rapid Pink-Eye Test; Detects Viral Conjunctivitis Infections in Minutes 3Health News:Foundation Radiology Group Signs Exclusive Contract With Uniontown Hospital 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 2Health News:TeamStaff, Inc. To Announce Third Quarter Results 3Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 2Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 3Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 4Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 5Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 6Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 7Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 8Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 9Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 10Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 11Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 12Health News:Cardium Reports on Second Quarter 2009 Financial Results and Recent Developments 13Health News:ValueOptions(R) Awards Coordination of Benefits and Overpayment Services Contract to HMS 2Health News:Florida Health Insurance Brokerage to Donate Month of August to Help Residents of Florida 2
... androgen secreted into the blood. In males, ... of the testes; in females ca. 50% ... of androstenedione, ca. 25% from the ovary ... The Testosterone ELISA KIT is based on ...
Microalbumin EIA Lipid / Protein Quantification 024-IDC-12...
Vitamin B6 REA Vitamin Assays, Cardiovascular 001-RK-VB6...
Myoglobin EIA Lipid / Protein Quantification, Cardiovascular 024-IDC-13 Muscle Disease...
Medicine Products: